Pseudolaric Acid A

Catalog No.E0249 Batch:E024901

Technical Data

Formula	C₂₂H₂₈O₆
Molecular Weight	388.45	CAS No.	82508-32-5
Solubility (25°C)*	In vitro	DMSO	78 mg/mL (200.79 mM)


* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

Pseudolaric acid A, a Hsp90 inhibitor with an IC50 of 0.60 μM, 2.72 μM, 1.36 μM, 2.92 μM and 6.16 μM in HL-60, A549, SMMC-7721, HeLa and SW480 cells respectively, is the main bioactive ingredient in Pseudolarix cortex, and induces cell cycle arrest at G2/M phase and promotes cell death through caspase-8/caspase-3 pathway, demonstrating potent antiproliferation and anticancer activities.

Targets

Hsp90 ^[1] (in HL-60 cells cytotoxicity assay)	Hsp90 ^[1] (in SMMC-7721 cells cytotoxicity assay)	Hsp90 ^[1] (in A549 cells cytotoxicity assay)	Hsp90 ^[1] (in HeLa cells cytotoxicity assay)	Hsp90 ^[1] (in SW480 cells cytotoxicity assay)
0.60 μM	1.36 μM	2.72 μM	2.92 μM	6.16 μM

In vitro

Pseudolaric Acid A is more sensitive to leukemia P-388 and melanoma SK-MEL5, suggesting it deserves further development as potentially useful antitumor agent.^[2]

Protocol (from reference)

Cell Assay:^{^[2]}	Cell lines KB, A-549, HCT-8, P-388, and L-1210 tumor cells Concentrations -- Incubation Time -- Method KB screen: The KB cells are maintained on Roswell Park Memorial Institute (RMPI) 1640 media supplemented with 5 % fetal calf serum and 100 µg/ml kanamycin. The cells (5 x 10<sup>4</sup>cell/ml) are plated 24 hours before the addition of Pseudolaric Acid A. All counting of KB cells is done on a hemacytometer. Results are expressed as the dose that inhibits growth to 50 % of control growth by three days after drug addition. P-388 and L-1210 screens: The P-388 lymphocytic leukemia and L- 1210 lymphoid leukemia cells are maintained in minimum essential medium (MEM) plus 10% fetal calf serum and 100 µg/ml penicillin/ streptomycin. Cells (10<sup>4</sup>) are incubated with Pseudolaric Acid A prepared in 0.05 % tween-80 NaCI. Cells are counted in control and treated tubes on day 3 using a hemacytometer. A-549, HCT-8 screens: Media used for the propagation and growth of these cell lines are F-12 with 10% fetal calf serum (FCS) for A-549, RPMI-1640 with sodium pyruvate and 10 % horse serum for HCT- 8. All media are treated with 50 ng/ml of gentocin to prevent bacterial contamination. The cells are grown in a humidified atmosphere of 5% CO2 and 95% air at 37℃. 24-well tissue culture plates are seeded each well with approximately 1 x 10<sup>4</sup>cells per 2 ml of growth medium and incubated at 37℃ overnight. The starting cell numbers in quadruplicate wells are determined by dispersing the monolayer with trypsin-EDTA solution and the total number of cells per well is determined. Pseudolaric Acid A in suitable concentration are added to quadruplicate wells in order to achieve a maximum treatment dosage of 10 µg/ml. After further incubation of the tissue culture plates at 37℃ for 72 h, the cell numbers in each well are determined.

Cell Assay:^{^[2]}

Cell lines
KB, A-549, HCT-8, P-388, and L-1210 tumor cells
Concentrations
--
Incubation Time
--
Method
KB screen: The KB cells are maintained on Roswell Park Memorial Institute (RMPI) 1640 media supplemented with 5 % fetal calf serum and 100 µg/ml kanamycin. The cells (5 x 104cell/ml) are plated 24 hours before the addition of Pseudolaric Acid A. All counting of KB cells is done on a hemacytometer. Results are expressed as the dose that inhibits growth to 50 % of control growth by three days after drug addition. P-388 and L-1210 screens: The P-388 lymphocytic leukemia and L- 1210 lymphoid leukemia cells are maintained in minimum essential medium (MEM) plus 10% fetal calf serum and 100 µg/ml penicillin/ streptomycin. Cells (104) are incubated with Pseudolaric Acid A prepared in 0.05 % tween-80 NaCI. Cells are counted in control and treated tubes on day 3 using a hemacytometer. A-549, HCT-8 screens: Media used for the propagation and growth of these cell lines are F-12 with 10% fetal calf serum (FCS) for A-549, RPMI-1640 with sodium pyruvate and 10 % horse serum for HCT- 8. All media are treated with 50 ng/ml of gentocin to prevent bacterial contamination. The cells are grown in a humidified atmosphere of 5% CO2 and 95% air at 37℃. 24-well tissue culture plates are seeded each well with approximately 1 x 104cells per 2 ml of growth medium and incubated at 37℃ overnight. The starting cell numbers in quadruplicate wells are determined by dispersing the monolayer with trypsin-EDTA solution and the total number of cells per well is determined. Pseudolaric Acid A in suitable concentration are added to quadruplicate wells in order to achieve a maximum treatment dosage of 10 µg/ml. After further incubation of the tissue culture plates at 37℃ for 72 h, the cell numbers in each well are determined.

References

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.